N/A N=51 Cardiovascular Complications of Sickle Cell Disease
Sickle Cell Disease
Primary: MRI Parameter - LVEDVi, mL/cm2 (Measured Using Method of Disks, Controls Serve as Normal Ranges) — 124.0; 78.7 mL/cm2 — p=0.0039
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=70 Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance
Impaired Glucose Tolerance · Prediabetic State
Primary: AIM 1: Change in Flow Mediated Dilation (FMD) (%) — -0.0012; 0.018; 0.014; 0.0053 percentage of arterial dilation change — p=0.943
N/A N=20 Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults
Prediabetes · Cardiovascular Disease
Primary: Vascular Endothelial Function — -294.4; -152.9; -102.9; -361.6 %FMD*min
N/A N=428 Cardiovascular Intervention Improvement Telemedicine Study
Cardiovascular Disease · Hypertension · Diabetes
Primary: Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent) — 32.4; 31.6 % 10 yr Risk
N/A N=69 The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults
Cardiovascular Diseases · Cardiovascular Abnormalities · Heart Attack
Primary: Change From Baseline of Total Cholesterol After 90 Days — -0.57; -1.09 mmol/L — p=0.042
N/A N=65 Singing and Cardiovascular Health in Older Adults
Cardiovascular Diseases · Cardiovascular Risk Factor · Cardiovascular Health
Primary: Change in FMD% — -0.06; -0.11; -0.06 FMD percent — p=0.864
N/A N=6,009 Cardiovascular Risk Screening and Risk Reduction in Women Vets
Cardiovascular Diseases · Hypertension · Hyperlipidemias
Primary: New Participation in MOVE! (Among Women Aged 65 and Older) — 1.09 Odds Ratio — p=.003
N/A N=10,347 Reducing Cardiovascular Risk in Adults With Serious Mental Illness
Chronic Disease · Mental Disorder · Health Behavior
Primary: Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke — 14.2; 20.8 percentage of annual rate of change
Phase 3 N=10,251 Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Atherosclerosis · Cardiovascular Diseases · Hypercholesterolemia
Primary: First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in…
Phase 4 N=76 Cardiovascular Function in COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI) in the 6th Week of Treatment — 2.855; 2.317 Millilitre/ meter^2 (mL/m^2) — p=0.6331
N/A N=2,039 Pathways to Cardiovascular Disease Prevention (DCRI Central and Statistical Coordinating Center)
HIV/AIDS · Cardiovascular Diseases
Primary: Number of Participants With Visit to a Cardiology Specialist From Cohort — 283 Participants
Phase 2 N=101 Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
Pre-hypertension
Primary: Change in Disease Score (DS) Among the Treatment Groups — -2.48; -2.29; -2.38; -0.96 Overall Rasmussen Disease Score Change
Phase 2 N=8 Healthy Heart Habits
Acute Coronary Syndrome · Depression
Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale
N/A N=112 The Effect of Reducing Posttraumatic Stress Disorder Symptoms on Cardiovascular Risk
PTSD
Primary: Change From Baseline to Post-Intervention in 24-hour Heart Rate Variability (HRV) Estimated From the Standard Deviation of the Interbeat Interval of Normal Sinus Beats…
N/A N=20 Sex Differences in Vascular Responses to Exercise
Aging
Primary: Change in FMD in Response to Chronic HIIT — 0.11; 0.57; 0.81; 0.10 % flow mediated dilation
Phase 2 N=34 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Metabolic Syndrome · Coronary Microvascular Dysfunction
Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005
N/A N=104,219 Cardiovascular Disease Population Risk Tool
Cardiovascular Diseases
Primary: Major Cardiovascular Disease Event — 3182; 527 Cardiovascular disease event
N/A N=66 Study of the Long-term Effects of Exercise on Heath Indicators in Older People
Hypertension With Complications and Secondary Hypertension · Overweight and Obesity · Lipid Metabolism Disorders
Primary: Cardiovascular Disease Risk Factors — 3; 4; 5; 7 participants
N/A N=51 PCI Alternative Using Sustained Exercise
Cardiovascular Disease
Primary: Myocardial Perfusion Reserve — 2.76; 2.47; 2.82; 2.52 Ratio
N/A N=58 Disease Management for Coronary Artery Patients
Patient Empowerment · Coronary Artery Disease
Primary: Compliance Questionnaire Scores of the Participants — 22.25; 22.53 score on a scale
N/A N=151 Systemic Lupus Erythematous and Heart Conduction Disorders
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
N/A N=22 Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Fat
Prediabetes
Primary: Vascular Endothelial Function — -195.9; -6.181; -5.629 %*min
Phase 4 N=36 MIcrovascular dysfuNction In Moderate-severe Psoriasis
Psoriasis · Cardiovascular Disease
Primary: Change in Global Coronary Flow Reserve (CFR) After 6 Months of Therapy With Tildrakizumab — -0.03 CFR Ratio
N/A N=21,664 Pre-Diabetes Cardiovascular (CV) Care (Pre-Diabetes Wizard)
Pre-diabetes
Primary: Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke — 1.100; 1.096 units on a scale — p=<0.05
N/A N=23 Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk
Prediabetes
Primary: Vascular Endothelial Function — -307; -34.8; -36.8; -110 %*min
N/A N=65,406 Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists
Pulmonary Disease, Chronic Obstructive
Primary: Occurrence of First Hospitalisation or Hospital Outpatient Clinic Visit for Atrial Fibrillation or Flutter (AF) — 246; 725 Events
Phase 3 N=47 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Diabetes, Type I · Diabetes, Type II · Angina
Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change
N/A N=269 Intervention Trial to Decrease Cardiovascular Risk in Persons With Serious Mental Illness
Cardiovascular Risk Factors · Serious Mental Illness
Primary: Global Framingham Risk Score — 11.5; 12.7; 9.9; 12.3 score on a scale
N/A N=202 Impact of a Corrie Cardiac Rehabilitation Program
Coronary Artery Disease · Myocardial Infarction · Myocardial Ischemia
Primary: 6-minute Walking Distance (Meters) — 506.1; 489.8 meters — p=0.04
Phase 3 N=118 Self-Management Addressing Heart Disease Risk Trial
Bipolar Disorder · Cardiovascular Disease
Primary: Systolic and Diastolic Blood Pressure (SBP, DBP) — 127.2; 130.4; 75.9; 78.5 mm/Hg — p=<.05